NuScale vs Oklo: Which of These Best Nuclear Stocks Offers Better Growth?

The nuclear energy sector is attracting significant investor attention, with next-generation reactor companies positioning themselves as transformative forces. NuScale Power (NYSE: SMR) and Oklo (NYSE: OKLO) represent two distinct approaches to scaling nuclear technology, each with compelling advantages and timelines that merit careful examination for those seeking the best nuclear stocks to add to their portfolios.

Contrasting Technologies in the Nuclear Stocks Landscape

The two companies employ fundamentally different reactor designs that address distinct market needs. NuScale manufactures small modular reactors (SMRs) featuring a compact design that maintains operational flexibility while scaling to substantial power outputs. The U.S. Nuclear Regulatory Commission has granted NuScale Standard Design Approvals for its 77 MW electric (MWe) reactor configuration, representing a significant regulatory achievement. This approval enables NuScale to construct a 462 MWe facility for Romania’s RoPower and supports its agreement with the Tennessee Valley Authority (TVA) to deploy up to six gigawatts of capacity across multiple states.

Oklo’s approach emphasizes microreactors—units even more compact than traditional SMRs. Its Aurora microreactor generates 1.5 MWe independently but can be interconnected to achieve 15-100 MWe per installation, offering unprecedented flexibility for remote and off-grid applications. Oklo differentiates itself through metallic uranium fuel pellets, which provide superior thermal resistance and reduced fabrication costs compared to conventional uranium dioxide fuel. Notably, Oklo’s systems recycle fuel in a closed-loop configuration, extending operational periods to approximately a decade without refueling—a substantial advantage over traditional reactors requiring refueling every two years.

Revenue Timelines and Near-term Deployment Catalysts

The path to commercial viability reveals a critical distinction between these best nuclear stocks. NuScale’s Romanian project, executed in partnership with Fluor Corporation, recently achieved its final investment decision but faces deployment timelines extending into the early 2030s. Similarly, the TVA initiative likely won’t commence operations until 2032. During the interim period—2025 through 2028—NuScale will generate revenue primarily through front-end engineering and design studies, converting memorandums of understanding into binding contracts, and licensing agreements. Analysts project this revenue stream could expand from $31 million to $287 million over this four-year horizon as the company narrows operational losses.

Oklo’s first commercial reactor in Idaho is scheduled for late 2027 deployment, positioning it ahead of NuScale in the operational timeline. The company anticipates $16 million in revenue for 2027, with accelerated growth as it expands beyond this initial installation. Oklo has secured a government contract for Eielson Air Force Base in Alaska and partnered with Siemens Energy for steam turbine and generator system production, indicating growing commercial momentum.

Valuation Disconnect: Why Oklo Commands a Premium

Market dynamics have created a striking valuation disparity between these nuclear stocks. Oklo’s $9.7 billion market capitalization translates to approximately 600 times its projected 2027 sales, reflecting speculative enthusiasm about microreactor potential. NuScale, with a $3.9 billion valuation, appears more reasonably priced at 19 times 2027 projected sales—though still representing a premium valuation structure typical of pre-revenue technology companies.

This valuation premium for Oklo reflects investor confidence in its earlier deployment timeline and technological differentiation, yet it simultaneously raises questions about sustainability. NuScale’s valuation offers clearer visibility into near-term catalysts, as its revenue-generating activities are commencing now despite delayed reactor deployments. The market’s preference for observable near-term development suggests continued near-term momentum for Oklo, even as NuScale possesses more identifiable paths to profitability.

The Investment Case for Nuclear Stocks in 2026

Evaluating best nuclear stocks requires balancing technological promise against commercial readiness and valuation reasonableness. NuScale demonstrates more established regulatory pathways and larger-scale deployment potential through its 462 MWe Romanian facility and multi-gigawatt TVA commitment. However, its significant stock price decline—roughly 80% from recent peaks—reflects market impatience with development timelines extending several years into the future.

Oklo’s microreactor architecture and earlier operational timeline position it as a near-term catalyst generator. Its 20% stock price correction, substantially less severe than NuScale’s decline, suggests market participants maintain confidence in its execution capabilities. The fundamental distinction is that Oklo’s smaller initial deployments don’t preclude NuScale’s success; both companies address differentiated market segments within the expanding nuclear energy sector.

For investors assessing which best nuclear stocks deserve portfolio allocation, the analysis hinges on time horizons and risk tolerance. NuScale offers substantial long-term potential supported by substantial government partnerships and approved designs, but near-term catalysts remain years away. Oklo provides more immediate commercial milestones beginning in 2027, though valuation remains aggressive relative to current revenue visibility. Both enterprises could generate substantial returns over the coming decade as global energy demands intensify and nuclear technology gains mainstream acceptance. The optimal choice depends on individual investment objectives and conviction regarding near-term versus long-term value creation in the nuclear energy transition.